2024 Agenda

In the whirlwind of the past few years, we've witnessed the pendulum of funding dynamics swing from the euphoria of 2021 to the recalibration of last year. This has spurred companies to think differently about managing cash burn, overcoming revenue headwinds, and securing funding. Against this backdrop, we bring together successful founders and CEOs to share what they are seeing, strategies for navigating this current environment and how they are charting their course for success in the years ahead.

In light of numerous and growing clinical workforce challenges, this panel will address best practices for clinician recruitment and retention. The panelists bring perspectives from a variety of provider organizations, both virtual and brick and mortar, and will discuss novel approaches to hiring MDs, nurses, PAs, and therapists, as well as the ways in which care team innovation can help with burnout and improve long-term provider satisfaction.

Interoperability has come a long way over the last decade, According to the ONC, 88% of hospitals participated in electronic data exchange in 2021. There are many different stakeholders and data exchange needs, and while transactions are definitely increasing, the coverage varies greatly between geographic areas and in different use cases and stakeholder considered. In this panel, we will explore these issues as well as industry trends.

Retail drug spending has increased from ~$90 per capita to ~$1,150 per capita, in 2021. This trend is unlikely to slow down due to numerous high-cost specialty drugs (e.g., gene therapies) and other blockbusters (e.g., GLP-1s). In this panel, we will discuss Digital Health's role in helping to control costs while maximizing quality and outcomes. We will explore ways digital health companies can partner with incumbents (e.g., payers, PBMs) and the unmet market needs that digital health could (or could not) solve. We will explore the impact of the Inflation Reduction Act’s Medicare Drug Price Negotiation Program.

As value-based care startups have proliferated over the last several years, we’re now seeing more nuanced conversations happening about the impact of value-based care on clinical, financial, and experience outcomes. This panel will focus on how leading investors view the latest trends in the market and lessons learned from their experiences supporting value-based care models. We’ll talk about what's driving where models have and have not found success, as well as opportunities looking forward. 

Recent advances in machine learning and artificial intelligence have resulted in astonishing feats of reasoning, creativity, and automation. These capabilities have led to a sense that this technology has the potential to help transform the future of medicine. But where do we start, where are we likely to see the greatest impact, and what are the most salient challenges in these early innings?